Appointed
Esi Eggleston Bracey
Director
lululemon athletica inc.
appointed Esi Eggleston Bracey as a member of the Board, effective April 28, 2026.
Executive movement radar
Source-linked appointments, departures, and role changes from SEC 8-K Item 5.02 filings. Every card cites the SEC source.
Showing 101–150 of 280
Departed
Leonel Peralta
Senior Vice President, Chief Operations Officer
ACCURAY INC
Leonel Peralta, Senior Vice President, Chief Operations Officer of Accuray Incorporated (the “Company”), departed from the Company effective April 26, 2026.
Appointed
Paul Taylor
Chairman of the Board and Chief Executive Officer
VISIUM TECHNOLOGIES, INC.
Effective April 27, 2026, Mr. Paul Taylor has assumed the positions of Chairman of the Board and Chief Executive Officer of Visium Technologies, Inc. (the “Company”).
Appointed
Cheddi Rai
Chief Technology Officer and Chief Operating Officer
VISIUM TECHNOLOGIES, INC.
Concurrently, Mr. Cheddi Rai has been appointed Chief Technology Officer and Chief Operating Officer of the Company.
Appointed
Eric Andersen
President and CEO
AMERICAN INTERNATIONAL GROUP, INC.
On April 27, 2026, the Board of Directors (the “Board”) of American International Group, Inc. (the “Company”) appointed Eric Andersen as President and CEO of the Company and a member of the Board, effective June 1, 2026
Role change
Peter Zaffino
Executive Chair of the Board
AMERICAN INTERNATIONAL GROUP, INC.
Upon the Effective Date, Peter Zaffino, the Company’s current Chairman and CEO, will assume the position of Executive Chair of the Board.
Appointed
Dr. Daniel Gilmer
member of the Board
ARMP ·
Armata Pharmaceuticals, Inc.
On April 27, 2026, Armata Pharmaceuticals, Inc. (the “Company”) announced that the Board of Directors (the “Board”) appointed Dr. Daniel Gilmer, 39, as a member of the Board, effective as of April 24, 2026, to serve until the Company’s next annual meeting of the Company’s shareholders.
Departed
Margaret G. McGlynn
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Departed
Eiry W. Roberts
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Appointed
Brian Mueller
Director
AMICUS THERAPEUTICS, INC.
The directors of Merger Sub immediately prior to the Effective Time were Eric Davis and Brian Mueller.
Departed
Ellen S. Rosenberg
Other Named Officer
AMICUS THERAPEUTICS, INC.
all executive officers of the Company immediately prior to the Effective Time (Bradley L. Campbell, Simon Harford, Ellen S. Rosenberg, David M. Clark and Jeffrey P. Castelli) ceased to be executive officers of the Surviving Corporation.
Departed
Burke W. Whitman
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Appointed
Eric Davis
President and Secretary
AMICUS THERAPEUTICS, INC.
Eric Davis, as President and Secretary of Merger Sub immediately prior to the Effective Time, became President and Secretary of the Surviving Corporation
Departed
Simon Harford
Other Named Officer
AMICUS THERAPEUTICS, INC.
all executive officers of the Company immediately prior to the Effective Time (Bradley L. Campbell, Simon Harford, Ellen S. Rosenberg, David M. Clark and Jeffrey P. Castelli) ceased to be executive officers of the Surviving Corporation.
Departed
Michael A. Kelly
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Departed
Bradley L. Campbell
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Departed
Craig A. Wheeler
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Departed
Michael G. Raab
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Departed
Lynn D. Bleil
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Departed
Glenn P. Sblendorio
Director
AMICUS THERAPEUTICS, INC.
each of the directors of the Company (Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler and Burke W. Whitman) resigned and ceased to be directors of the Company and members of any committee of the Company’s board of directors.
Departed
Jeffrey P. Castelli
Other Named Officer
AMICUS THERAPEUTICS, INC.
all executive officers of the Company immediately prior to the Effective Time (Bradley L. Campbell, Simon Harford, Ellen S. Rosenberg, David M. Clark and Jeffrey P. Castelli) ceased to be executive officers of the Surviving Corporation.
Appointed
Eric Davis
Director
AMICUS THERAPEUTICS, INC.
The directors of Merger Sub immediately prior to the Effective Time were Eric Davis and Brian Mueller.
Departed
David M. Clark
Other Named Officer
AMICUS THERAPEUTICS, INC.
all executive officers of the Company immediately prior to the Effective Time (Bradley L. Campbell, Simon Harford, Ellen S. Rosenberg, David M. Clark and Jeffrey P. Castelli) ceased to be executive officers of the Surviving Corporation.
Appointed
Brian Mueller
Treasurer
AMICUS THERAPEUTICS, INC.
Brian Mueller, as Treasurer of Merger Sub immediately prior to the Effective Time, became Treasurer of the Surviving Corporation
Departed
Bradley L. Campbell
Other Named Officer
AMICUS THERAPEUTICS, INC.
all executive officers of the Company immediately prior to the Effective Time (Bradley L. Campbell, Simon Harford, Ellen S. Rosenberg, David M. Clark and Jeffrey P. Castelli) ceased to be executive officers of the Surviving Corporation.
Appointed
Eric Sites
Director
MIAMI INTERNATIONAL HOLDINGS, INC.
On April 23, 2026, the board of directors (the “Board”) of Miami International Holdings, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Eric Sites as a director to the Board to fill an existing vacancy, effective as of April 24, 2026, until the 2026 Annual Meeting of Shareholders or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
Appointed
Troy Rillo
Chief Executive Officer
Texas Ventures Acquisition III Corp
On April 22, 2026, Mr. Troy Rillo was appointed as Chief Executive Officer of the Company by the Company’s board of directors, effective immediately.
Departed
Kevin McGurn
Chief Executive Officer
Texas Ventures Acquisition III Corp
On April 22, 2026, Mr. Kevin McGurn notified the board of directors of Texas Ventures Acquisition III Corp (the “Company”) of his resignation as Chief Executive Officer of the Company, effective immediately.
Appointed
Jason D. Sawyer
member of the Board
GRMLW ·
Greenland Mines Ltd
On April 17, 2026, the Board of Directors (the “Board”) of Greenland Mines Ltd. (the “Company”) appointed Jason D. Sawyer to serve as a member of the Board, effective immediately, to fill a vacancy on the Board.
Appointed
Heidi O'Neill
Chief Executive Officer
lululemon athletica inc.
On April 21, 2026, lululemon athletica inc. entered into an employment agreement with Heidi O’Neill whereby it agreed to appoint Ms. O’Neill as Chief Executive Officer and as a member of our board of directors, in each case effective September 8, 2026.
Appointed
Betsy K. Hood
Director
First Guaranty Bancshares, Inc.
First Guaranty Bancshares, Inc. ("First Guaranty") elected Ms. Betsy K. Hood to the Board of Directors for First Guaranty on April 16, 2026.
Departed
Stephen K. Klasko
Director
DCGO ·
DocGo Inc.
On April 17, 2026, Stephen K. Klasko, MD notified DocGo Inc. (the “Company”) of his decision to step down as a member of the Board of Directors (the “Board”) and his other Board and committee positions because he accepted a new significant healthcare leadership role, effective as of the conclusion of the Company’s 2026 Annual Meeting of Stockholders expected to be held on June 16, 2026 (the “Effective Time”).
Appointed
Michael Burdiek
Chair of the Board
DCGO ·
DocGo Inc.
The Board’s Nominating and Corporate Governance Committee and the Board reassessed the leadership of the Board and appointed Michael Burdiek, a long-serving independent member of the Board, as an independent Chair of the Board, effective as of the Effective Time
Departed
Janisha Sabnani
Other Named Officer
HERITAGE COMMERCE CORP
the individual pre-closing bonus amount for each of its named executive officers, which amounts were paid to the Heritage named executive officers whose employment will not continue following the Effective Time (Seth Fonti, Thomas Sa, and Janisha Sabnani).
Departed
Clay Jones
President and Chief Executive Officer
HERITAGE COMMERCE CORP
At the Effective Time, all directors and executive officers of Heritage and Heritage Bank ceased to serve in such capacities.
Departed
Seth Fonti
Other Named Officer
HERITAGE COMMERCE CORP
the individual pre-closing bonus amount for each of its named executive officers, which amounts were paid to the Heritage named executive officers whose employment will not continue following the Effective Time (Seth Fonti, Thomas Sa, and Janisha Sabnani).
Departed
Thomas Sa
Other Named Officer
HERITAGE COMMERCE CORP
the individual pre-closing bonus amount for each of its named executive officers, which amounts were paid to the Heritage named executive officers whose employment will not continue following the Effective Time (Seth Fonti, Thomas Sa, and Janisha Sabnani).
Appointed
Charles S. McKhann
Director
Envoy Medical, Inc.
On April 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the " Board ") of Envoy Medical, Inc. (the " Company "), the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.
Departed
Steven C. Gilman
Director
SCYNEXIS INC
On April 16, 2026, Steven C. Gilman, a member of the Board of Directors (the “Board”) of SCYNEXIS, Inc. (the “Company”), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”).
Appointed
Doug Hott
Chief Financial Officer
Snap Inc
In connection with the departure of Mr. Andersen, we plan to appoint Doug Hott, our current Vice President of Finance, Strategy, and Corporate Development, to serve as our Chief Financial Officer.
Departed
Derek Andersen
Chief Financial Officer
Snap Inc
On April 17, 2026, Derek Andersen, our Chief Financial Officer, notified us that he will leave Snap for a new professional opportunity.
Departed
Donald J. LaBauve Jr.
Chief Accounting Officer
ALBEMARLE CORP
On April 13, 2026, Donald J. LaBauve Jr. advised Albemarle Corporation (the “Company ”) of his intent to retire from his position as Chief Accounting Officer, effective June 1, 2026, following more than 36 years of service to the Company.
Appointed
Henry H. Du
director
Emmaus Life Sciences, Inc.
appointed Henry H. Du to fill the vacancy on the Board of Directors created by the recent resignation of Jon Kuwahara.
Departed
Jon Kuwahara
director
Emmaus Life Sciences, Inc.
appointed Henry H. Du to fill the vacancy on the Board of Directors created by the recent resignation of Jon Kuwahara.
Role change
Gustavo Garavaglia
President and Chief Executive Officer
IPALCO ENTERPRISES, INC.
appointed Gustavo Garavaglia as President and Chief Executive Officer of IPALCO and Chief Executive Officer of AES Indiana, effective April 15, 2026.
Appointed
Sherry Kohan
Vice President, Chief Financial Officer and Controller
IPALCO ENTERPRISES, INC.
elected Sherry Kohan as Vice President, Chief Financial Officer and Controller, and designated her as principal accounting officer, of IPALCO and AES Indiana, effective May 7, 2026.
Role change
Kenneth J. Zagzebski
Executive Chairman
IPALCO ENTERPRISES, INC.
Mr. Garavaglia replaces Kenneth J. Zagzebski, who had mutually determined with IPALCO and AES Indiana to cease serving as President and Chief Executive Officer and be appointed to serve as Executive Chairman of the Boards, also effective April 15, 2026.
Appointed
Robert J. Williams
Director
SCTH ·
Securetech Innovations, Inc.
nominated Robert J. Williams, CPA, age 66, to serve as an independent director and as a member of the Audit Committee, the Nomination Committee, and the Compensation Committee of the Board, subject to and effective upon the conditions described below.
Departed
James Gruber
Chief Financial Officer
Eton Pharmaceuticals, Inc.
Mr. Gruber will remain in his role with the Company through May 31, 2026 and will subsequently enter into a six-month consulting agreement with the Company.
Appointed
Judith Matthews
Chief Financial Officer
Eton Pharmaceuticals, Inc.
Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026.
Pilot corpus: a static 200-row sample of 8-K Item 5.02 filings; not a real-time live feed. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. See methodology.